Variantyx offers a comprehensive set of advanced genomic diagnostic products and services with a focus on whole genome sequencing.
Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditional step-wise, reiterative genetic testing.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 18, 2022 | Debt Financing | $20M | 1 |
![]() |
— | Detail |
Mar 15, 2021 | Series C | $20M | 1 |
|
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Debt Financing |
|
Yes | Series C |